Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Lowered by StockNews.com

Inovio Pharmaceuticals (NASDAQ:INO) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Monday.

A number of other analysts have also weighed in on INO. HC Wainwright reaffirmed a “neutral” rating and set a $3.00 price objective on shares of Inovio Pharmaceuticals in a research report on Wednesday, March 19th. Royal Bank of Canada cut their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research report on Wednesday, March 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $12.20.

Inovio Pharmaceuticals Stock Performance

INO opened at $1.92 on Monday. Inovio Pharmaceuticals has a one year low of $1.42 and a one year high of $13.44. The stock has a market capitalization of $70.41 million, a PE ratio of -0.48 and a beta of 1.40. The business’s 50 day moving average price is $1.80 and its 200 day moving average price is $2.56.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.23. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.01 million. As a group, equities research analysts forecast that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Large investors have recently bought and sold shares of the business. Barclays PLC boosted its stake in Inovio Pharmaceuticals by 15.0% in the fourth quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 5,111 shares in the last quarter. Geode Capital Management LLC boosted its stake in Inovio Pharmaceuticals by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock valued at $1,150,000 after acquiring an additional 6,874 shares in the last quarter. Northern Trust Corp boosted its stake in Inovio Pharmaceuticals by 6.4% in the fourth quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company’s stock valued at $401,000 after acquiring an additional 13,269 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Inovio Pharmaceuticals by 22.4% in the first quarter. Bank of New York Mellon Corp now owns 75,422 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 13,784 shares in the last quarter. Finally, XTX Topco Ltd boosted its stake in Inovio Pharmaceuticals by 26.7% in the first quarter. XTX Topco Ltd now owns 66,169 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 13,939 shares in the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.